We previously reported that AAT deficient patients, who received AAT therapy prior to but not after LuTx, show worse survival rates relative to AAT deficiency without prior augmentation or to AAT sufficient COPD patients [49]. This evidence concerns the gene SERPINA1 and chronic obstructive pulmonary disease.